Paul S. Weiner Sells 17,723 Shares of ConforMIS, Inc. (CFMS) Stock

ConforMIS, Inc. (NASDAQ:CFMS) CFO Paul S. Weiner sold 17,723 shares of the stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $3.17, for a total value of $56,181.91. Following the transaction, the chief financial officer now owns 162,009 shares in the company, valued at approximately $513,568.53. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Shares of ConforMIS, Inc. (CFMS) traded up $0.06 during mid-day trading on Friday, reaching $3.27. The company’s stock had a trading volume of 387,530 shares, compared to its average volume of 299,113. The company has a current ratio of 6.19, a quick ratio of 5.38 and a debt-to-equity ratio of 0.52. ConforMIS, Inc. has a 52 week low of $3.03 and a 52 week high of $9.59.

ConforMIS (NASDAQ:CFMS) last released its earnings results on Wednesday, November 1st. The medical instruments supplier reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.03. The business had revenue of $18.40 million for the quarter, compared to the consensus estimate of $17.55 million. ConforMIS had a negative return on equity of 76.88% and a negative net margin of 72.70%. The business’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same quarter last year, the business posted ($0.31) earnings per share. research analysts predict that ConforMIS, Inc. will post -1.28 EPS for the current year.

WARNING: “Paul S. Weiner Sells 17,723 Shares of ConforMIS, Inc. (CFMS) Stock” was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://sportsperspectives.com/2017/11/18/paul-s-weiner-sells-17723-shares-of-conformis-inc-cfms-stock.html.

A number of equities analysts have issued reports on CFMS shares. Zacks Investment Research downgraded ConforMIS from a “buy” rating to a “hold” rating in a research report on Tuesday, October 31st. Deutsche Bank AG reiterated a “hold” rating and set a $5.00 price target (down previously from $6.00) on shares of ConforMIS in a research report on Friday, August 4th. ValuEngine upgraded ConforMIS from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Canaccord Genuity lowered their price target on ConforMIS from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Friday, August 4th. Finally, BTIG Research reiterated a “hold” rating on shares of ConforMIS in a research report on Thursday, November 2nd. One analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the stock. ConforMIS currently has a consensus rating of “Hold” and an average price target of $5.85.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wells Fargo & Company MN lifted its position in shares of ConforMIS by 1.8% in the first quarter. Wells Fargo & Company MN now owns 53,930 shares of the medical instruments supplier’s stock valued at $282,000 after acquiring an additional 935 shares in the last quarter. Platinum Investment Management Ltd. lifted its position in shares of ConforMIS by 23.6% in the second quarter. Platinum Investment Management Ltd. now owns 335,156 shares of the medical instruments supplier’s stock valued at $1,437,000 after acquiring an additional 63,900 shares in the last quarter. Ark Investment Management LLC lifted its position in shares of ConforMIS by 208.5% in the second quarter. Ark Investment Management LLC now owns 192,378 shares of the medical instruments supplier’s stock valued at $825,000 after acquiring an additional 130,009 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of ConforMIS by 1,313.6% in the first quarter. Goldman Sachs Group Inc. now owns 148,147 shares of the medical instruments supplier’s stock valued at $773,000 after acquiring an additional 137,667 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of ConforMIS by 35.6% in the second quarter. Bank of New York Mellon Corp now owns 171,901 shares of the medical instruments supplier’s stock valued at $737,000 after acquiring an additional 45,096 shares in the last quarter. Institutional investors and hedge funds own 32.83% of the company’s stock.

About ConforMIS

ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.

Insider Buying and Selling by Quarter for ConforMIS (NASDAQ:CFMS)

Receive News & Ratings for ConforMIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply